Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.

ABSTRACT:

Purpose

Aggressive variant prostate cancer (AVPC) is a nonandrogen receptor-driven form of disease that arises in men in whom standard-of-care therapies have failed. Therapeutic options for AVPC are limited, and the development of novel therapeutics is significantly hindered by the inability to accurately quantify patient response to therapy by imaging. Imaging modalities that accurately and sensitively detect the bone and visceral metastases associated with AVPC do not exist.

Experimental design

This study investigated the transmembrane protein CD133 as a targetable cell surface antigen in AVPC. We evaluated the expression of CD133 by microarray and IHC analysis. The imaging potential of the CD133-targeted IgG (HA10 IgG) was evaluated in preclinical prostate cancer models u

SUBMITTER: Glumac PM 

PROVIDER: S-EPMC7056526 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature